The deubiquitinase BAP1 and E3 ligase UBE3C sequentially target IRF3 to activate and resolve the antiviral innate immune response
Cell Reports · 2024-08 · 43 (8) · 114608
DOI: 10.1016/j.celrep.2024.114608 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2024-08. Verfasst von Xiang Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Immunity and Inflammation, Institute of Immunology, Navy Medical University, Shanghai 200433, China; Department of Respira…. Hauptthemen laut MEDLINE: Tumor Suppressor Proteins, Ubiquitin Thiolesterase, Ubiquitin-Protein Ligases, Immunity, Innate. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Zhejiang Province Natural Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Ubiquitination is essential for the proteasomal turnover of IRF3, the central factor mediating the antiviral innate immune response. However, the spatiotemporal regulation of IRF3 ubiquitination for the precise activation and timely resolution of innate immunity remains unclear. Here, we identified BRCA1-associated protein-1 (BAP1) and ubiquitin-protein ligase E3C (UBE3C) as the key deubiquitinase and ubiquitinase for temporal control of IRF3 stability during viral infection. In the early stage, BAP1 dominates and removes K48-linked ubiquitination of IRF3 in the nucleus, preventing its proteasomal degradation and facilitating efficient interferon (IFN)-β production. In the late stage, E3 ligase UBE3C, induced by IFN-β, specifically mediates IRF3 ubiquitination and promotes its proteasomal degradation. Overall, the sequential interactions with BAP1 and UBE3C govern IRF3 stability during innate response, ensuring effective viral clearance and inflammation resolution. Our findings provide insights into the temporal control of innate signaling and suggest potential interventions in viral infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Key Laboratory of Immunity and Inflammation, Institute of Immunology, Navy Medical University, Shanghai 200433, China; Department of Respiratory Disease, Affiliated Xihu Hospital, Hangzhou Medical College, Hang…
- National Key Laboratory of Immunity and Inflammation, Institute of Immunology, Navy Medical University, Shanghai 200433, China.
- National Key Laboratory of Immunity and Inflammation, Institute of Immunology, Navy Medical University, Shanghai 200433, China; Department of Immunology, Institute of Basic Medical Sciences, Peking Union Medical College…
- National Key Laboratory of Immunity and Inflammation, Institute of Immunology, Navy Medical University, Shanghai 200433, China. Electronic address: xusheng@immunol.org.
Förderung
- Zhejiang Province Natural Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Liu, X., Cui, L., Tao, Y., Xia, S., Hou, J., Cao, X., & Xu, S. (2024). The deubiquitinase BAP1 and E3 ligase UBE3C sequentially target IRF3 to activate and resolve the antiviral innate immune response. Cell Reports, 43(8), 114608. https://doi.org/10.1016/j.celrep.2024.114608
Vancouver
Liu X, Cui L, Tao Y, Xia S, Hou J, Cao X, et al. The deubiquitinase BAP1 and E3 ligase UBE3C sequentially target IRF3 to activate and resolve the antiviral innate immune response. Cell Reports. 2024;43(8):114608. doi:10.1016/j.celrep.2024.114608
BibTeX
@article{Liu2024,
author = {Liu, Xiang and Cui, Likun and Tao, Yijie and Xia, Simo and Hou, Jin and Cao, Xuetao and Xu, Sheng},
title = {The deubiquitinase BAP1 and E3 ligase UBE3C sequentially target IRF3 to activate and resolve the antiviral innate immune response},
journal = {Cell Reports},
year = {2024},
volume = {43},
number = {8},
pages = {114608},
doi = {10.1016/j.celrep.2024.114608}
}
EUVIMED